Acute Respiratory Distress Syndrome (ARDS) Market Size Projected To Reach $2.17 Billion By 2034 With A Cagr Of 11.1%

The Acute Respiratory Distress Syndrome (ARDS) Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Projected Growth of the Acute Respiratory Distress Syndrome (ARDS) Market?
The market size for acute respiratory distress syndrome (ARDS) has seen rapid expansion in recent years. The market, which is projected to be worth $1.29 billion in 2024, is expected to increase to $1.42 billion by 2025, demonstrating a compound annual growth rate (CAGR) of 10.4%. The surge in growth during the historical period can be associated with the advancements in critical care medicine, an aging population, development in pulmonary rehabilitation, and the rise of multidisciplinary care teams.

The market size for acute respiratory distress syndrome (ARDS) is predicted to expand significantly in the coming years. It's projected to reach $2.17 billion by 2029, with a compound annual growth rate (CAGR) of 11.1%. The projected growth during this period is due to a variety of factors, including worldwide healthcare readiness, the development of vaccines, the management of infectious diseases, telemedicine and remote patient monitoring, as well as patient-oriented care models. Key trends expected during this forecast period comprise of artificial lung devices, custom ventilation strategies, lung protective ventilation, and specific drug therapies for different ARDS subtypes.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13005

What Are the Different Acute Respiratory Distress Syndrome (ARDS) Market Segments?
The acute respiratory distress syndrome (ARDS) market covered in this report is segmented -

1) By Type: Diagnosis, Treatment
2) By Cause: COVID-19 Disease 2019 (COVID-19), Sepsis, Inhalation Of Harmful Substances, Severe Pneumonia, Other Causes
3) By Severity: Mild, Moderate, Severe
4) By End User: Hospitals, Clinics, Ambulatory Service Centers, Other End Users

Subsegments:
1) By Diagnosis: Imaging Tests, Blood Tests, Lung Function Tests, Other Diagnostic Methods
2) By Treatment: Mechanical Ventilation, Medications, Extracorporeal Membrane Oxygenation (ECMO), Supportive Care, Other Treatment Options

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13005&type=smp

What Are the Primary Drivers Shaping the Acute Respiratory Distress Syndrome (ARDS) Market?
The rise in instances of pneumonia is likely to fuel the expansion of the acute respiratory distress syndrome (ARDS) market. Pneumonia, an infection impacting one or both lungs, leads to the inflating of the lungs' air cells, or alveoli, with fluid or pus. This infection triggers inflammation in the lungs which results in increased blood vessel permeability and the leakage of fluid into the alveoli, disrupting the exchange of oxygen and carbon dioxide, and causing respiratory distress. For example, data from the Centre for Tropical Medicine and Global Health, a leading UK-based healthcare research organization, indicates a considerable surge in pneumonia cases in Kenya in November 2023, with the number escalating to 793,864 in 2022-2023, a significant increase from the 477,186 cases of 2020-2021. Consequently, this rise in pneumonia occurrence is stimulating the growth of the acute respiratory distress syndrome (ARDS) market. Acute Respiratory Distress Syndrome (ARDS) Market Driver: The Rise in Respiratory Diseases Is Likely to Positively Influence the Acute Respiratory Distress Syndrome (ARDS) Market

Which Companies Are Leading in the Acute Respiratory Distress Syndrome (ARDS) Market?
Major companies operating in the acute respiratory distress syndrome (ards) market are Johnson & Johnson Services Inc., Novartis AG, GlaxoSmithKline PLC, Medtronic PLC, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Amgen Inc., Fresenius SE & Co. KGaA, Koninklijke Philips N.V., Baxter International Inc., Teva Pharmaceutical Industries Ltd., CSL Behring, Terumo Corporation, ResMed Inc., Smiths Medical Inc., Dräger Safety AG & Co. KGaA., Getinge AB, Mallinckrodt PLC, Masimo Corporation, United Therapeutics Corporation, Fisher & Paykel Healthcare Corporation Limited, Hamilton Medical AG, Zuventus Healthcare Ltd., Windtree Therapeutics Inc., Faron Pharmaceuticals Oy, AcelRx Pharmaceuticals Inc.

What Are the Major Trends Shaping the Acute Respiratory Distress Syndrome (ARDS) Market?
Leading firms in the acute respiratory distress syndrome (ARDS) sector are turning their attention to the creation of novel drugs and supplements such as Aviptadil, HSP90 inhibitors among others in order to solidify their market standing. Aviptadil, a specifically synthesized vasoactive intestinal peptide (VIP), binds specifically to lung alveolar type II cell receptors. As an example, in November 2022, India's pharmaceutical maker, Zuventus Healthcare Ltd. released Aviptadil as a treatment for acute respiratory distress syndrome. This vasoactive intestinal peptide supplement, Aviptadil, boosts oxygen intake and reduces death rates in patients with ARDS. It can achieve this by defending and regenerating type-2 Pneumocytes, reinvigorating type-1 Pneumocytes, boosting surfactant production, and reducing IL-6 (interleukin 6) and tumor necrosis factor (TNF)-alpha.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/acute-respiratory-distress-syndrome-ards-global-market-report

What Are the Top Revenue-Generating Geographies in the Acute Respiratory Distress Syndrome (ARDS) Market?
North America was the largest region in the acute respiratory distress syndrome (ARDS) market in 2024. The regions covered in acute respiratory distress syndrome (ARDS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Acute Respiratory Distress Syndrome (ARDS) Market?
2. What is the CAGR expected in the Acute Respiratory Distress Syndrome (ARDS) Market?
3. What Are the Key Innovations Transforming the Acute Respiratory Distress Syndrome (ARDS) Industry?
4. Which Region Is Leading the Acute Respiratory Distress Syndrome (ARDS) Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.